N-Acetylcysteine and Its Immunomodulatory Properties in Humans and Domesticated Animals
- PMID: 37891946
- PMCID: PMC10604897
- DOI: 10.3390/antiox12101867
N-Acetylcysteine and Its Immunomodulatory Properties in Humans and Domesticated Animals
Abstract
N-acetylcysteine (NAC), an acetylated derivative of the amino acid L-cysteine, has been widely used as a mucolytic agent and antidote for acetaminophen overdose since the 1960s and the 1980s, respectively. NAC possesses antioxidant, cytoprotective, anti-inflammatory, antimicrobial, and mucolytic properties, making it a promising therapeutic agent for a wide range of diseases in both humans and domesticated animals. Oxidative stress and inflammation play a major role in the onset and progression of all these diseases. NAC's primary role is to replenish glutathione (GSH) stores, the master antioxidant in all tissues; however, it can also reduce levels of pro-inflammatory tumor necrosis factor-alpha (TNF-∝) and interleukins (IL-6 and IL-1β), inhibit the formation of microbial biofilms and destroy biofilms, and break down disulfide bonds between mucin molecules. Many experimental studies have been conducted on the use of NAC to address a wide range of pathological conditions; however, its effectiveness in clinical trials remains limited and studies often have conflicting results. The purpose of this review is to provide a concise overview of promising NAC usages for the treatment of different human and domestic animal disorders.
Keywords: N-acetylcysteine; antioxidant; cytoprotective; glutathione; immunomodulatory agent; oxidative stress.
Conflict of interest statement
The authors declare no conflict of interest. Authors Armen Charchoglyan, Lauri Wagter-Lesperance, Byram Bridle, Bonnie A. Mallard, and Niel A. Karrow are team members of ImmunoCeutica Inc. One of ImmunoCeutica’s goals is to educate the global community to pursue and apply knowledge to bring about a positive change in healthcare, which includes the use of immunoceuticals when warranted. ImmunoCeutica currently has no NAC-related product, and the members of the team were involved in mentoring the primary student author in the collection, analysis, and interpretation of data, as well as in the writing of the manuscript.
Figures
References
-
- Center for Food Safety and Applied Nutrition . FDA Releases Final Guidance on Enforcement Discretion for Certain NAC Products. FDA; Rockville, MD, USA: 2023.
Publication types
LinkOut - more resources
Full Text Sources
